NovaBay receives $2.6M to advance Aganocide research

NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.

Related Videos
Related Content

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023
© 2023 MJH Life Sciences

All rights reserved.